vTv Therapeutics (FRA:5VT0) ROC (Joel Greenblatt) %: 0.00% (As of Mar. 2026)


FRA:5VT0 vTv Therapeutics Inc FRA:5VT0
35 GF Score
Price €28.60
GF Value €6,924.34
View Full Analysis

What is vTv Therapeutics ROC (Joel Greenblatt) %?

vTv Therapeutics FRA:5VT0 -3.38% 35 ROC (Joel Greenblatt) % is 0.00% as of Mar. 2026. GuruFocus rates FRA:5VT0 with a GF Score™ of 35/100 and a GF Value™ of €6,924.34. Among 1,320 Biotechnology companies, vTv Therapeutics ranks worse than 77.95% on this metric.

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. vTv Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 0.00%.

The historical rank and industry rank for vTv Therapeutics's ROC (Joel Greenblatt) % or its related term are showing as below:

FRA:5VT0' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -13962.86   Med: -5660.41   Max: -1307.07
Current: -2603.14

During the past 13 years, vTv Therapeutics's highest ROC (Joel Greenblatt) % was -1307.07%. The lowest was -13962.86%. And the median was -5660.41%.

FRA:5VT0's ROC (Joel Greenblatt) % is ranked worse than
77.95% of 1320 companies
in the Biotechnology industry
Industry Median: -294.23 vs FRA:5VT0: -2603.14

vTv Therapeutics's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


vTv Therapeutics  (FRA:5VT0) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


vTv Therapeutics ROC (Joel Greenblatt) % Related Terms


vTv Therapeutics ROC (Joel Greenblatt) % Historical Data

* Premium members only.

The historical data trend for vTv Therapeutics's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

vTv Therapeutics ROC (Joel Greenblatt) % Chart

vTv Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2,396.92 -4,164.33 -5,560.51 -6,522.05 0.00

vTv Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -23,359.22 -32,067.07 -73,416.67 -76,187.50 0.00

FRA:5VT0 vs SMNR, CNTB, ENLV: ROC (Joel Greenblatt) % Comparison

For the Biotechnology subindustry, vTv Therapeutics's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


vTv Therapeutics ROC (Joel Greenblatt) % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, vTv Therapeutics's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where vTv Therapeutics's ROC (Joel Greenblatt) % falls into.


FRA:5VT0
35GF Score
vTv Therapeutics Inc FRA:5VT0
ROC (Joel Greenblatt) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

vTv Therapeutics ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.82100000000001) - (3.823 + 0 + 1.848)
=-4.85

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.625) - (5.9 + 0 + 0.052)
=-5.327

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of vTv Therapeutics for the quarter that ended in Mar. 2026 can be restated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=80.488/( ( (0 + max(-4.85, 0)) + (0 + max(-5.327, 0)) )/ 1 )
=80.488/( ( 0 + 0 )/ 1 )
=80.488/0
= %

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROC (Joel Greenblatt) % of 0.00% mean?
vTv Therapeutics (FRA:5VT0) has a ROC (Joel Greenblatt) % of 0.00% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on vTv Therapeutics and its competitors. According to the industry distribution chart, vTv Therapeutics ranks #1029 out of 1320 companies in the Biotechnology industry, placing it in the top 78%.
Is vTv Therapeutics' ROC (Joel Greenblatt) % too high?
vTv Therapeutics' current ROC (Joel Greenblatt) % is 0.00%. Based on the distribution chart, vTv Therapeutics ranks #1029 out of 1320 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, vTv Therapeutics has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does vTv Therapeutics' ROC (Joel Greenblatt) % compare to SMNR and CNTB?
According to the Biotechnology industry distribution chart, vTv Therapeutics ranks #1029 out of 1320 companies for ROC (Joel Greenblatt) %. This places vTv Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Biotechnology company?
A good ROC (Joel Greenblatt) % depends on the Biotechnology industry context. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on vTv Therapeutics and its competitors. vTv Therapeutics's current ROC (Joel Greenblatt) % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is vTv Therapeutics stock overvalued right now?
vTv Therapeutics (FRA:5VT0) has a current ROC (Joel Greenblatt) % of 0.00%. The stock's GF Value™ is €6,924.34, compared to a current price of €28.60 — trading 99.6% below its estimated fair value. The current ROC (Joel Greenblatt) % is 0.00%. vTv Therapeutics' overall GF Score™ is 35/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For vTv Therapeutics (FRA:5VT0), the current ROC (Joel Greenblatt) % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is vTv Therapeutics (FRA:5VT0) Overvalued in 2026?

Based on GuruFocus' analysis, vTv Therapeutics stock appears to be undervalued. The current stock price of €28.60 is trading 99.6% below its estimated GF Value™ of €6,924.34.

Key valuation signals for FRA:5VT0:

  • ROC (Joel Greenblatt) %: 0.00%
  • GF Value™: €6,924.34 vs. price of €28.60 (99.6% below fair value)
  • GF Score™: 35/100

No single metric tells the full story. See the FRA:5VT0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


vTv Therapeutics Business Description

Other Exchanges VTVT:USA
Address 3980 Premier Drive, Suite 110, High Point, NC, USA, 27265
vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small-molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), a novel, small-molecule, liver-selective glucokinase activator (GKA) currently being evaluated as a potential oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). In addition, the company is also engaged in the research and development of other candidates in its pipeline through collaborations with academic partners and license agreements, which include TTP273, HPP737, TTP-RA, Mavodelpar (HPP593), HPP971, and HPP3033, being studied and developed to counter various chronic diseases.
35GF Score

Get the complete analysis for FRA:5VT0

ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€28.60
Price
€6,924.34
GF Value